Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Hizentra

Phase 2Biologic

Hizentra is one of 88 biologic programs targeting Immunodeficiency. It is currently in Phase 2.

2

Indications

5

Total Trials

2

Active Trials

87

Competitors

Pipeline

Status by Indication[3][1]

Indication

ImmunodeficiencyActive, not recruiting

Myasthenia GravisActive, not recruiting

ImmunodeficiencyPhase 2/Phase 3

Active, not recruiting

Myasthenia GravisPhase 2

Active, not recruiting

Competition

Competitive Landscape

296 competitors in Immunodeficiency

#DrugCompanyPhaseTrials

Farxiga

Viread

Repatha

Edurant Ped

Retrovir

BBp Consulting, Inc

Prezista

Truvada

B/F/TAF

FTC/TDF

PPSV23

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

HIES

NCT04672733

Post-ApprovalRecruiting

Airway Disease

NCT05193552

Clinical

Trials by Indication[1]

Immunodeficiency1 trial

Humoral Immunodeficiency in CLL and Therapy With Subcutaneous Ig

Completed·RRochester General Hospital·Phase 2/3·NCT03730129·20 enrolled

HIES1 trial

Hizentra® in Inflammatory Neuropathies - pHeNIx Study

Recruiting· CSL Behring logo

CSL Behring··NCT04672733·100 enrolled

Myasthenia Gravis1 trial

Open Label Study of Subcutaneous Immunoglobulin (SCIg) in Myasthenia Gravis

Completed·—·Phase 2·NCT02100969·23 enrolled

Airway Disease1 trial

Usage of Spirometry in Managing IgG Therapy in CVID with Airway Disease

Recruiting·UUniversity of Alabama at Birmingham·Phase 4·NCT05193552·22 enrolled

Efficacy1 trial

Evaluation of Efficacy and Tolerability of Hizentra®

Unknown status·UUniversity of South Florida·N/A·NCT01354587·50 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Hizentra. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Hizentra compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Hizentra. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — CSL Behring company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: CSL Behring

Related News